Butorphanol prevents morphine-induced pruritus without increasing pain and other side effects: a systematic review of randomized controlled trials
- First Online:
- Cite this article as:
- Du, BX., Song, ZM., Wang, K. et al. Can J Anesth/J Can Anesth (2013) 60: 907. doi:10.1007/s12630-013-9989-4
- 1k Downloads
Pruritus is a frequent adverse event after administration of morphine. Butorphanol has been used to prevent morphine-induced pruritus, but its efficacy is still controversial. The aim of this systematic review was to evaluate the efficacy of using butorphanol to prevent morphine-induced pruritus.
We searched PubMed, Cochrane Library, EMBASE, and China’s BioMedical Disc for full reports of randomized controlled trials that compared the use of butorphanol with either placebo or no treatment for preventing morphine-induced pruritus. The number of patients experiencing pruritus or other side effects was analyzed using relative risk (RR) with 95% confidence intervals (CI).
Sixteen trials (795 patients) were analyzed. Continuous intravenous and epidural butorphanol reduced pruritus with RR 0.22 (95% CI 0.10 to 0.45) and RR 0.24 (95% CI 0.16 to 0.36), respectively. Use of epidural butorphanol decreased the number of patients requesting rescue treatment for pruritus (RR 0.57; 95% CI 0.41 to 0.81). Butorphanol decreased postoperative pain intensity at four, eight, and 12 hr with standardized mean differences of −0.29 (95% CI −0.52 to −0.05), −0.30 (95% CI −0.56 to −0.04), and −0.23 (95% CI −0.46 to −0.01), respectively. Epidural but not intravenous butorphanol reduced postoperative nausea and vomiting (PONV) (RR 0.35; 95% CI 0.19 to 0.66). Butorphanol did not increase respiratory depression (RR 0.71; 95% CI 0.31 to 1.63), somnolence (RR 0.71; 95% CI 0.22 to 2.37), or dizziness (RR 2.45; 95% CI 0.35 to 17.14).
Butorphanol administered with morphine may be an effective strategy for preventing morphine-induced pruritus as it decreases pain intensity and PONV without increasing other side effects. Thus, it can be recommended for preventing morphine-induced pruritus during the perioperative period.
Le butorphanol prévient le prurit induit par la morphine sans augmentation de la douleur et des autres effets secondaires: une revue méthodique des études randomisées contrôlées
Le prurit est un effet secondaire néfaste fréquent après l’administration de morphine. Le butorphanol a été utilisé pour prévenir le prurit induit par la morphine, mais son efficacité est encore controversée. L’objectif de cette revue méthodique était d’évaluer l’efficacité du butorphanol pour prévenir le prurit induit par la morphine.
Nous avons effectué une recherche dans les bases de données PubMed, Cochrane Library, EMBASE, et le BioMedical Disc chinois pour en extraire les comptes rendus d’études randomisées contrôlées comparant l’utilisation de butorphanol vs. un placebo ou aucun traitement pour prévenir le prurit induit par la morphine. Le nombre de patients souffrant de prurit ou d’autres effets secondaires a été analysé en étudiant le risque relatif (RR) avec des intervalles de confiance (IC) de 95 %.
Au total, 16 études (795 patients) ont été analysées. Le butorphanol en administration intraveineuse continue et en péridurale a réduit le prurit avec un RR de 0,22 (IC 95 % 0,10 à 0,45) et un RR de 0,24 (IC 95 % 0,16 à 0,36), respectivement. L’utilisation de butorphanol a réduit le nombre de patients nécessitant un traitement de secours pour le prurit (RR 0,57; IC 95 % 0,41 à 0,81). Le butorphanol a réduit l’intensité de la douleur postopératoire à quatre, huit et 12 h avec des différences moyennes normalisées de −0,19 (IC 95 % −0,52 à −0,05), −0,30 (IC 95 % −0,56 à −0,04) et −0,23 (IC 95 % −0,46 à −0,01), respectivement. Le butorphanol administré en péridurale mais non en intraveineuse a réduit les nausées et vomissements postopératoires (NVPO) (RR 0,35; IC 95 % 0,19 à 0,66). Le butorphanol n’a pas augmenté la dépression respiratoire (RR 0,71; IC 95 % 0,31 à 1,63), la somnolence (RR 0,71; IC 95 % 0,22 à 2,37), ou les étourdissements (RR 2,45; IC 95 % 0,35 à 17,14).
Le butorphanol administré conjointement à la morphine pourrait constituer une stratégie efficace pour prévenir le prurit induit par la morphine, étant donné qu’il réduit l’intensité de la douleur et les NVPO sans augmenter les autres effets secondaires. Dès lors, on peut recommander son utilisation pour la prévention du prurit induit par la morphine pendant la période périopératoire.
The administration of opioids is one of the most common analgesic methods during and after a surgical procedure. Morphine is a frequently used opioid that can provide effective perioperative analgesia; however, it is often accompanied by a wide variety of troublesome side effects.1 Pruritus is an major adverse effect after morphine administration with a reported incidence of 30-100% following neuraxial administration of opioids2 and 10-50% following intravenous administration.3 Currently, the exact mechanism of morphine-induced pruritus is unclear.
Butorphanol, a synthetic opioid that exhibits partial agonist and antagonist activity at the μ-opioid receptors and agonist activity at the κ-opioid receptors4 has been approved by the United States Food and Drug Administration for the management of pain. Butorphanol has been used in clinical practice for musculoskeletal pain, migraine headaches,5 and perioperative analgesia and has shown a good safety profile when added to a perioperative regimen.6,7 Advantages of butorphanol include few adverse effects, low addiction potential, and low toxicity.8 The most frequently reported adverse effects of butorphanol include somnolence, dizziness, and nausea or vomiting.5
Due to its activity on the μ- and κ-opioid receptors, butorphanol could be an effective prophylactic treatment for morphine-induced pruritus while administered with morphine; however, there are conflicting results regarding the efficacy of this approach. It remains unclear whether the addition of butorphanol could influence the analgesia effect of morphine or induce other side effects.
The purpose of this systematic review was to evaluate the efficacy and safety of butorphanol in preventing morphine-induced pruritus in perioperative analgesia.
This systematic review was conducted according to the PRISMA recommendations for improving the quality of meta-analysis.9
We conducted a comprehensive search for all published reports of randomized controlled trials testing the effect of prophylactic systemic (intravenous, epidural, intramuscular, subcutaneous, oral, and transdermal) administration of butorphanol compared with placebo or no treatment. Both groups were in combination with morphine for perioperative analgesia. The relevant studies reported data regarding morphine-induced pruritus.
Exclusion criteria included trials studying the treatment of established pruritus with butorphanol and studies combining butorphanol with other anti-pruritus agents.
We searched PubMed, Cochrane Library, EMBASE and China’s BioMedical Disc without restriction on the year or language of the published articles. The following keywords were used in our search: pruritus or itching, butorphanol, morphine, operative or surgical, postoperative or postsurgical, anesthesia, analgesia, randomized or randomised, and controlled. The last search was conducted in November 2012. The reference lists of the original research, reviews, letters to the editor, and case reports were also scanned to identify studies not included in the computerized databases.
Two authors (D.B.X. and S.Z.M.) independently reviewed all articles identified for inclusion through the literature search. Any disagreement was adjudicated among all authors.
Data extraction process
A computerized spreadsheet (Microsoft Excel 2007) was created for data extraction. Two authors (D.B.X. and S.Z.M.) independently extracted relevant information from the original reports. Any disagreement was solved by decision among all authors.
The primary end point of efficacy was the incidence of pruritus with butorphanol compared with control. Itching was considered equivalent to pruritus. The number of patients requesting rescue treatment for pruritus was another end point.
To record pain intensity, a postoperative visual analogue scale (VAS) ranging from 0 mm (no pain) to 100 mm (worst pain) was extracted as means with standard deviations. Data were also extracted for other postoperative adverse events associated with morphine and butorphanol, e.g., postoperative nausea and vomiting (PONV), respiratory depression, dizziness, and somnolence.
Furthermore, the extracted information included the regimens of morphine and butorphanol, the number of patients in the experimental and control groups, and the type of surgery.
Risk of bias in individual studies
Two authors (D.B.X. and S.Z.M.) independently assessed the risk of bias in the included studies according to the guidelines recommended by the Cochrane collaboration.10 The risk of bias was assessed in six categories, including sequence generation, allocation, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias. Each domain was judged in accordance with three rulings: Yes indicated a low risk of bias; No indicated a high risk of bias; and Unclear indicated an unclear risk of bias. Any disagreement was settled through discussion with a third author (W.K.).
Relative risk (RR) with 95% confidence interval (CI) was computed for dichotomous outcomes extracted as the presence or absence of an effect. A formal heterogeneity test was performed, and a P value was used to assess heterogeneity among trials. If P value was < 0.1, the hypothesis of homogeneity was rejected and the following techniques were used: 1) subgroup analysis; 2) a random effects model; and 3) sensitivity analysis by excluding the trials that potentially biased the results. For the VAS pain score, a standardized mean difference (SMD) with 95% CI was computed.
The potential publication bias regarding our primary variable RR was evaluated by Egger’s test and a funnel plot. In Egger’s tests, P < 0.05 implies an existing publication bias. A fail-safe number was calculated to assess the stability of our results if publication bias was found.
Statistical analysis was conducted using Review Manager Version 5.0.24 (Cochrane Collaboration, Oxford, UK) and Stata® v10.0 (Stata Corp, College Station, TX, USA) software.
Quality assessment of this review
The AMSTAR rating scale, a measurement tool to assess the methodological quality of systematic reviews, was used to assess the quality of this review. The AMSTAR criteria11 include: 1) a priori design; 2) duplicate study selection and data extraction; 3) comprehensive literature search; 4) inclusive publication status; 5) included/excluded studies provided; 6) characteristics of included studies provided; 7) quality assessment of studies; 8) study quality used appropriately in formulating conclusions; 9) appropriate methods used to combine studies; 10) publication bias assessed; and 11) conflict of interest stated.
Characteristics of the selected randomized controlled trials
Comparison ( ) = number of analyzed patients
Yao et al.12
1. morphine 2 mg epid + placebo iv (20)
2. morphine 2 mg epid + butorphanol 160 μg·hr−1iv (20)
3. morphine 2 mg epid + butorphanol 240 μg·hr−1iv (20)
4. morphine 2 mg epid + butorphanol 280 μg·hr−1iv (20)
Wu et al.13
1. morphine 0.1 mg i.t. + placebo iv (45)
2. morphine 0.1 mg i.t. + butorphanol (1 mg + 200 μg·hr−1) iv (46)
Wu et al.14
Radical resection of rectal carcinoma
1. morphine 2 mg + placebo epid (30)
2. morphine 2 mg + butorphanol 1 mg epid (30)
Yu et al.15
1. morphine 20 μg·kg−1·hr−1 i.h. (30)
2. morphine 20 μg·kg−1·hr−1 + butorphanol 10 μg·kg−1·hr−1 i.h. (30)
Xiao et al.16
1. morphine 2 mg + 120 μg·hr−1 epid (30)
2. morphine (2 mg + 120 μg·hr−1) + butorphanol (0.5 mg + 30 μg·hr−1) epid (30)
Yi et al.17
1. morphine 2 mg + placebo epid (25)
2. morphine 2 mg + butorphanol 1 mg epid (25)
Yokoyama et al.18
1. morphine 3.3 mg·d−1 epid (20)
2. morphine 3.3 mg·d−1 + butorphanol 2 mg·d−1 epid (20)
Ding et al.19
1. morphine 2 mg epid (20)
2. morphine 2 mg + butorphanol 2 mg epid (20)
Sakai et al.20
1. morphine 0.1 mg i.t. + placebo iv (10)
2. morphine 0.1 mg i.t. + butorphanol 2 mg iv (10)
Gunter et al.21
1. morphine 50 μg·kg−1 + 6 μg·kg−1·hr−1 epid (18)
2. morphine (50 μg·kg−1 + 6 μg·kg−1·hr−1) + butorphanol (10 μg·kg−1 + 1.2 μg·kg−1·hr−1) epid (28)
Lawhorn et al.22
Spinal, abdominal or thoracic
1. morphine 80 μg·kg−1 epid (10)
2. morphine 80 μg·kg−1 + butorphanol 40 μg·kg−1 epid (10)
Lawhorn et al.23
1. morphine 80 μg·kg−1 epid (7)
2. morphine 80 μg·kg−1 + butorphanol 40 μg·kg−1 epid (7)
Bailey et al.24
Abdominal or thoracic surgery
1. morphine 60 μg·kg−1 epid (20)
2. morphine 60 μg·kg−1 epid + butorphanol 30 μg·kg−1epid (20)
3. morphine 60 μg·kg−1 epid + butorphanol 30 μg·kg−1iv (20)
Gambling et al.25
1. morphine 3 mg + placebo epid (23)
2. morphine 3 mg + butorphanol 1 mg epid (10)
3. morphine 3 mg + butorphanol 2 mg epid (21)
4. morphine 3 mg + butorphanol 3 mg epid (17)
Wittels et al.26
1. morphine 4 mg epid (25)
2. morphine 4 mg + butorphanol 4 mg epid (28)
Lawhorn et al.27
1. morphine 4 mg epid (10)
2. morphine 4 mg + butorphanol 1 mg epid (10)
3. morphine 4 mg + butorphanol 3 mg epid (10)
The methodological quality of the included studies
The characteristics of all included trials are shown in Table 1. The eligible studies were published from 1991-2012 in three languages: English (nine studies), Chinese (six studies),12,14-17,19 and Japanese (one study).18 Sample sizes ranged from 14-91 patients. Surgery included Cesarean delivery (seven studies), hysterectomy (two studies), radical resection of rectal carcinoma (one study), dorsal rhizotomy (one study), and not specified or a composite of different surgeries (five studies). The observation period of the included trials ranged from 24-75 hr, with one17 not reported.
The incidence of pruritus
The primary outcome in 11 trials was the incidence of pruritus.12-19,22-24 On average, 51.4% (132/257) of patients receiving morphine without butorphanol experienced pruritus. Trials were assigned into different subgroups according to the routes of butorphanol administration, but it was impossible to test the dose-response relationship of butorphanol because few trials used the same dose.
Intravenous butorphanol was administered in three trials, but the heterogeneity test showed that the data were not homogeneous (P < 0.1). One possible cause was the route of butorphanol in one trial, i.e., an intravenous bolus, which differed from the others. The estimation performed after this trial was excluded and a random effects model was used. The difference was significant (RR 0.22; 95% CI 0.10 to 0.45) (Fig. 3).
Subcutaneous butorphanol was tested in only one trial15 and was reported more effective than placebo in decreasing the incidence of pruritus (13.3% vs 36.7%, respectively).
The request for rescue treatment of pruritus
The effect of a single injection of intravenous butorphanol on the number of patients requesting rescue treatment for pruritus was evaluated in one trial.24 The data showed that a single injection of intravenous butorphanol was not effective in decreasing the number of patients requesting rescue treatment for pruritus when compared with placebo (45% vs 40%, respectively).
Postoperative pain intensity
Prevention of PONV
The effect of epidural butorphanol on PONV was reported in eight trials. The combined data showed a significant effect on preventing nausea and vomiting (RR 0.35; 95% CI 0.19 to 0.66) (Fig 7).
Respiratory depression, dizziness, and somnolence
Incidence of various side effects with butorphanol vs placebo
Four trials reported the incidence of somnolence. In one trial,24 the number of patients experiencing somnolence was unusually high (47% and 39% of 20 patients in each group) and was excluded. In the other three trials, four of 68 (5.9%) patients with morphine/butorphanol combination and five of 55 (9.1%) patients with morphine alone experienced somnolence. No significant difference was found (RR 0.71; 95% CI 0.22 to 2.37) (Table 2).
Five trials reported the incidence of dizziness with intravenous or epidural butorphanol combined with morphine. In these trials, 20 of 175 (11.4%) patients with morphine/butorphanol combination and 13 of 136 (9.6%) patients with morphine alone suffered dizziness. No significant difference was found (RR 2.45; 95% CI 0.35 to 17.14) (Table 2).
Quality of this review
We used the AMSTAR quality criteria to assess the strengths of this review and meta-analysis. In our review, the excluded studies were not provided and the conflict of interest was not stated. As a result, this review met nine of the 11 AMSTAR quality criteria, which indicated high quality.30
Pruritus is an uncomfortable sensation on the skin that often makes patients restless. Currently, the mechanism underlying morphine-related pruritus remains uncertain, but morphine-induced pruritus is considered mediated by the μ-opioid receptors31 and the κ-opioid receptors.32,33 Accordingly, administration of butorphanol (a partial μ- opioid receptor antagonist and κ-opioid receptor agonist) with morphine (μ- and κ-receptor agonist) would be expected to maintain analgesia (μ- and κ-receptors) while reducing pruritus.21 Butorphanol has been used to treat intractable pruritus based on its potential anti-pruritus effect,5 but debate on the efficacy of prophylactic butorphanol on morphine-induced pruritus still exists. This systematic review was designed to evaluate the impact of butorphanol on morphine-induced pruritus in perioperative analgesia. The results of this analysis indicated that prophylactic administration of epidural and continuous intravenous butorphanol significantly decreased the incidence of pruritus associated with morphine.
There were two earlier systematic reviews34,35 on the pharmacological intervention of opioid-induced pruritus, but both did not focus on butorphanol and studies of pediatric patients were excluded. In our systematic review, four trials in children were available, and the combined data from three trials reporting the occurrence of pruritus showed that butorphanol could significantly reduce morphine-induced pruritus.
The number of patients requesting rescue treatment for pruritus was selected to assess the efficacy of butorphanol in preventing pruritus, and this was reported in five trials. Four of the five trials showed negative results, while only one trial concluded that epidural butorphanol was effective. Nevertheless, in our meta-analysis, we pooled all data of patients to raise the evidence level, which resulted in a more precise and credible conclusion to show the efficacy of epidural butorphanol.
In addition, continuous infusion and single injection of intravenous butorphanol differed in the effects they had on preventing pruritus. For continuous intravenous infusion of butorphanol, the combined data of two trials12,13 suggested that it had a significant effect on preventing pruritus. On the other hand, when intravenous butorphanol was administered by single injection, the incidence of pruritus,24 the number of patients requesting treatment for pruritus,24 and the VAS scores for pruritus20,24 did not decrease when compared with control. The distinct effects in preventing pruritus might result from the different pharmacokinetics of the two regimens of butorphanol.36
Small-size and low-quality trials often overestimate the benefits of treatment;37 therefore, sensitivity analysis was performed in our review. The effect of epidural butorphanol on the incidence of pruritus was re-analyzed after excluding one study with a small group size and one study with a high risk of bias. The combined data still showed that epidural butorphanol could decrease the incidence of pruritus, which indicated that our result was stable. The fail-safe number, a value of 202, was also used to evaluate the reliability of our result, and it indicated that the meta-analysis would require a large number of non-significant associations to negate the significance.29
In our review, we also investigated whether butorphanol decreases the analgesic efficacy of morphine while improving pruritus. The VAS pain score was used to evaluate the efficacy of postoperative analgesia, and results indicated that a butorphanol-morphine combination could decrease postoperative pain intensity at four to 24 hr and did not worsen postoperative pain at 48 hr. This effect is attributed to the partial agonistic activity of butorphanol on μ1- and κ-receptors that are correlated with pain.21
Our meta-analysis also suggests that epidural, but not intravenous butorphanol, provided a significant decrease in the incidence of PONV when compared with placebo or control. Earlier experiments38 showed that elements involved in the mechanism of nausea and vomiting were not considered equally sensitive to intravenous and epidural opioid receptor antagonists, which could explain the difference in effectiveness between the two routes of administering butorphanol.
Moreover, butorphanol administered with morphine did not increase the incidence of other potential side effects. Clinically, respiratory depression is one of the most feared side effects of opioids. The addition of butorphanol to morphine in the range of doses tested in these trials did not increase the incidence of respiratory depression. Intravenous butorphanol increased the Ramsay sedation score at 24 hr13 and the incidence of somnolence,26 but epidural butorphanol did not cause any difference in the incidence of somnolence. Dizziness is a common side effect of butorphanol,39 but our synthetic result indicated that butorphanol did not increase the incidence of dizziness.
Our quality assessment based on AMSTAR criteria indicated high-quality strength in this systematic review. Nevertheless, our review has some limitations. First, we found evidence of publication bias using Egger’s test and a funnel plot. Publication bias tends to occur when “positive” studies are more likely to be published in English, although all published studies and abstracts were included and there was no language restriction in this systematic review. Even so, the fail-safe number was 202, which indicated the stability of our results. Second, the included studies in our review have different patient populations, surgical procedures, and lengths of follow-up, which caused clinical heterogeneity when meta-analysis was performed. Third, there might be a selection bias in our analyses of other side effects apart from pruritus; for example, we analyzed the data of postoperative pain, PONV, respiratory depression, dizziness, and somnolence from trials that were systematically searched for a different purpose. Lastly, since most studies included in our review were of small size, they potentially overestimate therapeutic effects and underrate relevant side effects.
Our systematic review summarizes the current scientific knowledge on the role of butorphanol to prevent postoperative morphine-induced pruritus. This review also raises recommendations for further research, for instance, more trials are needed to evaluate the effect of butorphanol on established pruritus, as there are few studies on this subject.5,40 This review suggests that intravenous and epidural butorphanol may differ in their effects on preventing pruritus, but there was only one trial24 in which a head-to-head comparison was performed between intravenous and epidural butorphanol. In addition, more high-quality randomized double-blind trials with a reasonable number of patients and a proper length of follow-up are needed to provide data on the efficacy, dose-responsiveness, and optimal routes of administering butorphanol to prevent pruritus and other side effects.
In conclusion, the current systematic review shows the potential benefits of using butorphanol to prevent morphine-induced pruritus and decrease pain intensity and PONV without increasing other side effects.